Literature DB >> 11751114

Increased glycan chain length distribution and decreased susceptibility to moenomycin in a vancomycin-resistant Staphylococcus aureus mutant.

Hitoshi Komatsuzawa1, Kouji Ohta, Sakuo Yamada, Kerstin Ehlert, Harald Labischinski, Junko Kajimura, Tamaki Fujiwara, Motoyuki Sugai.   

Abstract

A vancomycin-resistant Staphylococcus aureus mutant, COL-VR1 (MIC, 16 microg/ml), was isolated from methicillin-resistant S. aureus COL by exposure to vancomycin. COL-VR1 also showed decreased susceptibility to teicoplanin (8-fold), methicillin (2-fold), macarbomycin (8-fold), and moenomycin (16-fold). Macarbomycin and moenomycin are thought to directly inhibit transglycosylase activity. Characterization of the mutant revealed a thickened cell wall and suppression of penicillin-induced lysis, although the amounts of the five penicillin-binding proteins (PBPs 1, 2, 3, 4, and 2') and the profiles of peptidoglycan hydrolases were not altered. Analysis of muropeptide profile and glycan chain length distribution by reversed-phase high-pressure liquid chromatography revealed slightly decreased peptide cross-linking and an increased average glycan chain length compared to those of the parent. These results together suggest that a transglycosylase activity was enhanced in the mutant. This may represent a novel mechanism of glycopeptide resistance in S. aureus.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11751114      PMCID: PMC126989          DOI: 10.1128/AAC.46.1.75-81.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  35 in total

1.  Gradual alterations in cell wall structure and metabolism in vancomycin-resistant mutants of Staphylococcus aureus.

Authors:  K Sieradzki; A Tomasz
Journal:  J Bacteriol       Date:  1999-12       Impact factor: 3.490

2.  Heterogeneous vancomycin resistance in methicillin-resistant Staphylococcus aureus strains isolated in a large Italian hospital.

Authors:  A Marchese; G Balistreri; E Tonoli; E A Debbia; G C Schito
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

3.  Involvement of multiple genetic loci in Staphylococcus aureus teicoplanin resistance.

Authors:  M Bischoff; M Roos; J Putnik; A Wada; P Glanzmann; P Giachino; P Vaudaux; B Berger-Bächi
Journal:  FEMS Microbiol Lett       Date:  2001-01-01       Impact factor: 2.742

4.  Characterization of Staphylococcus aureus cell wall glycan strands, evidence for a new beta-N-acetylglucosaminidase activity.

Authors:  I G Boneca; Z H Huang; D A Gage; A Tomasz
Journal:  J Biol Chem       Date:  2000-04-07       Impact factor: 5.157

5.  Cloning and characterization of a gene, pbpF, encoding a new penicillin-binding protein, PBP2B, in Staphylococcus aureus.

Authors:  H Komatsuzawa; G H Choi; K Ohta; M Sugai; M T Tran; H Suginaka
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

6.  Moenomycin, an inhibitor of cell wall synthesis.

Authors:  G Huber; G Nesemann
Journal:  Biochem Biophys Res Commun       Date:  1968-01-11       Impact factor: 3.575

7.  Contribution of a thickened cell wall and its glutamine nonamidated component to the vancomycin resistance expressed by Staphylococcus aureus Mu50.

Authors:  L Cui; H Murakami; K Kuwahara-Arai; H Hanaki; K Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

8.  Inactivation of a novel three-cistronic operon tcaR-tcaA-tcaB increases teicoplanin resistance in Staphylococcus aureus.

Authors:  M Brandenberger; M Tschierske; P Giachino; A Wada; B Berger-Bächi
Journal:  Biochim Biophys Acta       Date:  2000-10-18

9.  A spectrum of changes occurs in peptidoglycan composition of glycopeptide-intermediate clinical Staphylococcus aureus isolates.

Authors:  S Boyle-Vavra; H Labischinski; C C Ebert; K Ehlert; R S Daum
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

10.  Clinical isolate of vancomycin-heterointermediate Staphylococcus aureus susceptible to methicillin and in vitro selection of a vancomycin-resistant derivative.

Authors:  S Bobin-Dubreux; M E Reverdy; C Nervi; M Rougier; A Bolmström; F Vandenesch; J Etienne
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

View more
  11 in total

1.  Cell wall composition and decreased autolytic activity and lysostaphin susceptibility of glycopeptide-intermediate Staphylococcus aureus.

Authors:  Jennifer L Koehl; Arunachalam Muthaiyan; Radheshyam K Jayaswal; Kerstin Ehlert; Harald Labischinski; Brian J Wilkinson
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

2.  Transcriptomic and functional analysis of an autolysis-deficient, teicoplanin-resistant derivative of methicillin-resistant Staphylococcus aureus.

Authors:  Adriana Renzoni; Christine Barras; Patrice François; Yvan Charbonnier; Elzbieta Huggler; Christian Garzoni; William L Kelley; Paul Majcherczyk; Jacques Schrenzel; Daniel P Lew; Pierre Vaudaux
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

3.  Novel mechanism of antibiotic resistance originating in vancomycin-intermediate Staphylococcus aureus.

Authors:  Longzhu Cui; Akira Iwamoto; Jian-Qi Lian; Hui-min Neoh; Toshiki Maruyama; Yataro Horikawa; Keiichi Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

4.  Characteristic cell wall ultrastructure of a macrolide-resistant Staphylococcus capitis strain isolated from a patient with chronic sinusitis.

Authors:  Yukiyoshi Hyo; Sakuo Yamada; Tamotsu Harada
Journal:  Med Mol Morphol       Date:  2008-09-20       Impact factor: 2.309

5.  DNA microarray-based identification of genes associated with glycopeptide resistance in Staphylococcus aureus.

Authors:  Longzhu Cui; Jian-Qi Lian; Hui-Min Neoh; Ethel Reyes; Keiichi Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

6.  Reduced content of lysyl-phosphatidylglycerol in the cytoplasmic membrane affects susceptibility to moenomycin, as well as vancomycin, gentamicin, and antimicrobial peptides, in Staphylococcus aureus.

Authors:  Hiromi Nishi; Hitoshi Komatsuzawa; Tamaki Fujiwara; Nadine McCallum; Motoyuki Sugai
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

7.  Morphological and genetic differences in two isogenic Staphylococcus aureus strains with decreased susceptibilities to vancomycin.

Authors:  Andrea Reipert; Kerstin Ehlert; Thomas Kast; Gabriele Bierbaum
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

8.  Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II.

Authors:  Christopher S Lunde; Stephanie R Hartouni; James W Janc; Mathai Mammen; Patrick P Humphrey; Bret M Benton
Journal:  Antimicrob Agents Chemother       Date:  2009-05-26       Impact factor: 5.191

9.  Staphylococcus aureus susceptibility to innate antimicrobial peptides, beta-defensins and CAP18, expressed by human keratinocytes.

Authors:  Kazushige Midorikawa; Kazuhisa Ouhara; Hitoshi Komatsuzawa; Toshihisa Kawai; Sakuo Yamada; Tamaki Fujiwara; Kenshi Yamazaki; Koji Sayama; Martin A Taubman; Hidemi Kurihara; Koji Hashimoto; Motoyuki Sugai
Journal:  Infect Immun       Date:  2003-07       Impact factor: 3.441

10.  Mutation in the C-di-AMP cyclase dacA affects fitness and resistance of methicillin resistant Staphylococcus aureus.

Authors:  Vanina Dengler; Nadine McCallum; Patrick Kiefer; Philipp Christen; Andrea Patrignani; Julia A Vorholt; Brigitte Berger-Bächi; Maria M Senn
Journal:  PLoS One       Date:  2013-08-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.